YK Bioventures

Investment decisions are made by co-founders Michael Chen and Timothy Lu, who serve as managing partners. Both hold active academic appointments — Chen at Stanford in bioengineering and Lu at MIT in biological engineering. The firm operates without a large investment committee structure, allowing the partners to move quickly on early-stage scientific opportunities they evaluate directly.

The firm sources deal flow primarily through the founders' academic networks at Stanford, MIT, and affiliated institutions. Both principals actively publish and peer-review in synthetic biology and CRISPR-related fields, giving them early visibility into lab-stage discoveries. This embedded model allows the firm to engage with scientific teams before they formally seek venture funding, often leading to pre-seed rounds where traditional firms are absent.

YK Bioventures has not publicly stated sector exclusions, but its disclosed portfolio demonstrates a tight focus on therapeutics enabled by synthetic biology, AI-driven drug discovery platforms, and digital health infrastructure. The firm does not appear to invest in medical devices, healthcare services delivery, or later-stage biotechnology companies where clinical risk has been substantially retired.

YK Bioventures concentrates exclusively on direct equity investments in operating companies. There is no public evidence of the firm making fund commitments to other venture managers or participating as a limited partner in third-party funds. This aligns with its operator-investor model, where the principals' scientific expertise is applied directly to company formation and governance.